Kymera Therapeutics, Inc. — Form 10-Q
Filed October 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Kymera Therapeutics entered a consulting agreement with Jared Gollob, MD effective October 1, 2026, through December 31, 2026. Under Work Order No. 1, Gollob will provide senior executive-level advisory and operational support for investor relations strategy and clinical trial execution at $3,000/week ($300/hour, max 10 hours/week). The agreement also preserves Gollob's previously vested stock options, exercisable for 90 days post-termination. Compensation is non-exclusive, terminable at will by the company, and includes standard IP assignment and confidentiality provisions.
Why this rating
Routine consulting arrangement (~$156k annually if full term); modest relative to $2.3B market cap. Standard advisory engagement with no material strategic or financial impact disclosed.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.